ABL1 / JTK7 / p150 Protein (GST Tag)

Tyrosine-Protein Kinase ABL1 ( ABL1 / JTK7 ) Protein

ABL1 / JTK7 Protein Product Information

• Synonym: ABL1, RP11-83J21.1, ABL, JTK7, bcr/abl, c-ABL, p150, v-abl
• Protein Construction: A DNA sequence encoding the amino acid sequence (Pro 137- Ser 554) of human ABL1 isoform B (NP_009297.2) was fused with the GST tag at the N-terminus
• Source: Human
• Expression Host: Baculovirus-Insect cells

ABL1 / JTK7 Protein QC Testing

• Purity: > 92 % as determined by SDS-PAGE
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method
• Stability: Samples are stable for up to twelve months from date of receipt at -70℃
• Predicted N terminal: Met
• Molecular Mass: The recombinant human ABL1/GST chimera consists of 645 amino acids and predicts a molecular mass of 74 kDa. It migrates as an approximately 65 KDa band in SDS-PAGE under reducing conditions
• Formulation: Lyophilized from sterile 50mM Tris,100mM NaCl, 0.5mM PMSF, 0.5mM EDTA, 0.5mM Reduced Glutathione, pH 8.0
• SDS-PAGE: ABL1 protein

ABL1 / JTK7 Protein Usage Guide

• Storage: Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

ABL1 / JTK7 Protein Description

Tyrosine-protein kinase ABL1, also known as Abelson murine leukemia viral oncogene homolog 1, ABL1, ABL, and JTK7, is a widely expressed protein which belongs to the protein kinase superfamily, Tyr protein kinase family and ABL subfamily. ABL1 contains one protein kinase domain, one SH2 domain and one SH3 domain. ABL1 regulates cytoskeleton remodeling during cell differentiation, cell division and cell adhesion. ABL1 localizes to dynamic actin structures, and phosphorylates CRK and CRKL, DOK1, and other proteins controlling cytoskeleton dynamics. ABL1 regulates DNA repair potentially by activating the proapoptotic pathway when the DNA damage is too severe to be repaired. ABL1 phosphorylates PSMA7 that leads to an inhibition of proteasomal activity and cell cycle transition blocks. ABL1 is stabilized in the inactive form by an association between the SH3 domain and the SH2-TK linker region. ABL1 is activated by autophosphorylation as well as by SRC-family kinase-mediated phosphorylation. It is activated by RIN1 binding to the SH2 and SH3 domains. ABL1 is inhibited by imatinib mesylate (Gleevec) which is used for the treatment of chronic myeloid leukemia (CML). It is also inhibited by VX-680, an inhibitor that acts also on imanitib-resistant mutants.

References

1. Han L.et al., 1997, Proc. Natl. Acad. Sci. USA. 94:4954-9. 
2. Wisniewski D.et al., 1999, Blood 93: 2707-20.
3. Liu X.et al., 2006, Mol. Cell 22: 317-27.
4. Young M.A.et al., 2006, Cancer Res. 66:1007-14. 
5. Nagar B.et al., 2006, Mol. Cell 21:787-98.